Biotech

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 18.10.2023.

NASDAQ
United States
Market capitalization
Therapy
Biotechnology
Liver

@Genetic Engineering & Biotechnology News shared
On Oct 18, 2023
Fake tweet - https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-drop-ahead-of-retail-sales-tesla-stock-falls-on-recall/
Open
@Genetic Engineering & Biotechnology News shared
On Oct 12, 2023
Fake tweet - https://www.lesswrong.com/posts/9a7fixEi5pEfKbMAc/what-i-ve-been-reading-october-2023-the-stirrup-in-europe
Open
What I've been reading, October 2023: The stirrup in Europe, 19th-century art deco, and more

What I've been reading, October 2023: The stirrup in Europe, 19th-century art deco, and more

A ~monthly feature. Last month was busy for me with a lot of travel and a lot of focus on The Roots of Progress as a nonprofit organization, so I hav…

@Genetic Engineering & Biotechnology News shared
On Oct 15, 2023
Fake tweet - https://markets.businessinsider.com/news/stocks/stock-market-outlook-ozempic-wegovy-glp1-weight-loss-drugs-investing-2023-10
Open
The stock market is getting Ozempic'ed

The stock market is getting Ozempic'ed

The collective shedding of billions of pounds thanks to GLP-1 drugs is poised reshuffle trillions of dollars in the stock market and economy.

@Genetic Engineering & Biotechnology News shared
On Oct 17, 2023
Fake tweet - https://www.marketwatch.com/story/biontechs-stock-sinks-after-disclosing-expected-charge-of-up-to-nearly-1-billion-resulting-from-pfizers-write-offs-of-covid-products-59df2d35
Open
BioNTech’s stock sinks after disclosing expected charge of up to nearly $1 billion resulting from Pfizer’s write offs of COVID products

BioNTech’s stock sinks after disclosing expected charge of up to nearly $1 billion resulting from Pfizer’s write offs of COVID products

Shares of BioNTech SE sank 6.1% toward a 2 1/2-year low in premarket trading Monday, after the Germany-based biotechnology company disclosed that it...

@Genetic Engineering & Biotechnology News shared
On Oct 18, 2023
Fake tweet - https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0293010
Open
The vitamin D receptor agonist EB1089 can exert its antiviral activity independently of the vitamin D receptor

The vitamin D receptor agonist EB1089 can exert its antiviral activity independently of the vitamin D receptor

Vitamin D has been shown to have antiviral activity in a number of different systems. However, few studies have investigated whether the antiviral activity is exerted through the vitamin D ...

@Genetic Engineering & Biotechnology News shared
On Oct 15, 2023
Fake tweet - https://economictimes.indiatimes.com/markets/stocks/news/near-4000-surge-catapults-one-tiny-biotech-firm-to-record-week/articleshow/104414942.cms
Open
Near-4,000% surge catapults one tiny biotech firm to record week

Near-4,000% surge catapults one tiny biotech firm to record week

Shares of Tempest have come off that high in the two latest trading sessions as investor enthusiasm moderated and a broader market selloff in risky assets batters the high-risk ...

@Genetic Engineering & Biotechnology News shared
On Oct 18, 2023
Fake tweet - https://www.forbes.com/sites/johnnavin/2023/10/16/3-nasdaq-biotechs-with-new-52-week-highs/
Open
3 Nasdaq Biotechs With New 52-Week Highs

3 Nasdaq Biotechs With New 52-Week Highs

Biotech stocks are having a bad year with the XBI trending downward for months now, but at least 3 Nasdaq-traded biotechnology companies are now hitting 52-week highs:...

@Genetic Engineering & Biotechnology News shared
On Oct 14, 2023
Fake tweet - https://fortune.com/2023/10/13/tempest-therapeutics-shares-surge-after-roche-led-cancer-treatment-trial/
Open
Why a biotech firm’s market value jumped from $3 million to $130 million in a day and is still way up from its ‘almost unfathomably low valuation’

Why a biotech firm’s market value jumped from $3 million to $130 million in a day and is still way up from its ‘almost unfathomably low valuation’

Results from a Roche-Run liver cancer trial involving Tempest Therapeutics' experimental therapy sent its shares surging.